Format

Send to

Choose Destination
Infect Drug Resist. 2012;5:163-73. doi: 10.2147/IDR.S29180. Epub 2012 Nov 29.

Current management options for latent tuberculosis: a review.

Author information

1
Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA.

Abstract

Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve completion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.

KEYWORDS:

interferon-gamma release assay; isoniazid; rifampin; rifapentine; tuberculin skin test

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center